Results 221 to 230 of about 98,914 (270)

Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
This meta‐analysis compared Resmetirom and Efruxifermin in patients with MASH, focusing on improvements in key biochemical and non‐invasive markers. Efruxifermin is associated with favourable outcomes with a slightly greater effect on MRI‐PDFF and AST, along with more comparable safety outcomes.
Doha Jaber   +4 more
wiley   +1 more source

The Gastrointestinal Safety of Orforglipron, a GLP‐1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta‐Analysis of Randomized Controlled Trials

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
In a network meta‐analysis of five RCTs including 3594 adults with or without type 2 diabetes (T2DM), orforglipron demonstrated dose‐dependent gastrointestinal adverse events (GI AE) and modest ALT reduction at higher doses, without increasing pancreatitis or hepatic event risk over 26 weeks, supporting a safety profile consistent with the Glucagon ...
Ahmed W. Hageen   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy